Listed

Clorox Co: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on Apr 30, 2021 and accepted by EDGAR at Apr 30, 2021, 16:15 ET.

Share

Management's discussion and analysis

As filed, 43,182 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(Dollars in millions, except per share data)

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. The following discussion of the Company’s financial condition and results of operations should be read in conjunction with MD&A and the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which was filed with the SEC on August 13, 2020, and the unaudited condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q (this Report). Unless otherwise noted, MD&A compares the three and nine month periods ended March 31, 2021 (the current period) to the three and nine month periods ended March 31, 2020 (the prior period), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate.

EXECUTIVE OVERVIEW

Clorox is a leading multinational manufacturer and marketer of consumer and professional products with approximately 8,800 employees worldwide. Clorox sells its products primarily through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products, Pine-Sol® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Fresh Step® cat litter; Glad® bags and wraps; Kingsford® grilling products; Hidden Valley® dressings; Brita® water-filtration products; Burt’s Bees® natural personal care products; and RenewLife®, Rainbow Light®, Natural Vitality®, NeoCell® and Stop Aging Now® vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro™ and the Clorox Healthcare® brand names. The Company has operations in more than 25 countries or territories and sells its products in more than 100 markets.

The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products compete with other nationally advertised brands within each category and with “private label” brands.

The Company operates through strategic business units (SBUs) which are also the Company’s operating segments. These SBUs are then aggregated into four reportable segments. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020. The four reportable segments consist of the following:

  • Health and Wellness consists of cleaning products, professional products, and vitamins, minerals and supplement products mainly marketed and sold in the U.S. Products within this segment include cleaning products such as laundry additives, including bleach products under the Clorox® brand and Clorox 2® stain fighter and color booster; home care products, primarily under the Clorox®, Clorox® Scentiva®, Formula 409®, Liquid-Plumr®, Pine-Sol® and Tilex® brands; professional cleaning and disinfecting products under the CloroxPro™, Clorox Healthcare®, and Clorox® Total 360® brands and professional food service products under the Hidden Valley® brand; and vitamins, minerals and supplement products under the RenewLife®, Rainbow Light®, Natural Vitality®, NeoCell® and Stop Aging Now® brands.
  • Household consists of grilling products; bags and wraps; and cat litter products marketed and sold in the U.S. Products within this segment include grilling products under the Kingsford® and Kingsford® Match Light® brands; bags and wraps under the Glad® brand; and cat litter products under the Fresh Step®, Scoop Away® and Ever Clean® brands.
  • Lifestyle consists of food products, water-filtration systems and filters, and natural personal care products marketed and sold in the U.S. Products within this segment include dressings and sauces, primarily under the Hidden Valley® brand; water-filtration systems and filters under the Brita® brand; and natural personal care products under the Burt’s Bees® brand.
  • International consists of products sold outside the U.S. Products within this segment include laundry additives; home care products; water-filtration systems and filters; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products primarily under the Clorox®, Ayudin®, Clorinda®, Poett®, Pine-Sol®, Glad®, Brita®, RenewLife®, Ever Clean® and Burt’s Bees® brands.

RECENT EVENTS RELATED TO COVID-19

The novel coronavirus (COVID-19) pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties. As a result, we have taken an active role in addressing the ongoing pandemic’s impact on our employees, operations, customers, consumers, and communities, including taking precautionary measures, such as implementing contingency plans, making operational adjustments where necessary, and providing support to organizations that support front-line workers. The impact of COVID-19 and responses of governments, consumers, and others to the pandemic are affecting our business in many ways; however, we believe that the actions we are taking will help us emerge from this global pandemic operationally sound, and well positioned for continued long-term growth.

For our fiscal third quarter ended March 31, 2021, we continued to experience elevated demand for many of our products, especially our disinfecting cleaning products, in response to COVID-19 in comparison to periods before the pandemic. The extent of COVID-19’s effect on our operational and financial performance in the future will depend on future developments, including the duration, spread and intensity of the pandemic, our continued ability to manufacture and distribute our products, as well as any future government actions affecting consumers and the economy generally, all of which are uncertain and difficult to predict considering the rapidly evolving landscape.

For additional information on the impacts and our response to the coronavirus pandemic, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

RESULTS OF OPERATIONS

CONSOLIDATED RESULTS

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Net sales $1,781 $1,783 —% $5,539 $4,738 17%
Three Months Ended March 31, 2021 Percentage change versus the year-ago period Reported (GAAP) Net Sales Growth / (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price/Mix/Other (1) Organic Sales Growth / (Decrease) (Non-GAAP) (2) Organic Volume (3)
Health and Wellness (8)% (11)% —% —% 3% (8)% (11)%
Household 6 4 — — 2 6 4
Lifestyle — (1) — — 1 — (1)
International 9 2 7 (2) 7 4 (3)
Total —% (4)% 1% —% 4% (1)% (5)%
Nine Months Ended March 31, 2021
Percentage change versus the year-ago period
Reported (GAAP) Net Sales Growth / (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact Price/Mix/Other (1) Organic Sales Growth / (Decrease) (Non-GAAP) (2) Organic Volume (3)
Health and Wellness 19% 15% —% —% 4% 19% 15%
Household 20 14 — — 6 20 14
Lifestyle 8 8 — — — 8 8
International 17 13 8 (4) 7 13 6
Total 17% 13% 1% —% 4% 16% 12%

(1) This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.

(2) Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of any acquisitions and divestitures as well as changes in foreign exchange rate.

(3) Organic volume represents volume excluding the effect of any acquisitions and divestitures. In the three months ended March 31, 2021, the volume impact of acquisitions was 5% and 1% for International and Total Company, respectively. In the nine months ended March 31, 2021, the volume impact of acquisitions was 7% and 1% for International and Total Company, respectively.

Net sales in the current three month period was essentially flat when compared to the prior period, reflecting lower sales in the Health and Wellness reportable segment, partially offset by sales growth in the Household and International reportable segments. Volume decreased by 4% versus the prior period. The variance between volume growth and net sales growth was primarily due to the impact of lower trade promotion spending and favorable mix.

Net sales in the current nine month period increased by 17%, reflecting higher shipments across all reportable segments driven by increased demand due to COVID-19 and related behavioral shifts. Volume increased by 13% versus the prior period. The variance between volume growth and net sales growth was primarily due to the impact of favorable mix, partially offset by unfavorable foreign currency exchange rates.

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Gross profit $774 $832 (7)% $2,531 $2,134 19%
Gross margin 43.5% 46.7% 45.7% 45.0%

Gross margin, defined as gross profit as a percentage of net sales, decreased by 320 basis points in the current three month period from 46.7% to 43.5%. The decrease was primarily driven by higher manufacturing and logistics costs and unfavorable commodity costs, partially offset by lower trade promotion spending and the benefit of cost savings initiatives.

Gross margin increased by 70 basis points in the current nine month period from 45.0% to 45.7%. The increase was primarily driven by higher volume, cost savings, and lower trade promotion spending, partially offset by higher manufacturing and logistics costs.

Three Months Ended 3/31/2021 3/31/2020 % Change % of Net Sales 3/31/2021 3/31/2020
Selling and administrative expenses $237 $269 (12)% 13.3% 15.1%
Advertising costs 200 184 9 11.2 10.3
Research and development costs 32 39 (18) 1.8 2.2
Nine Months Ended
% of Net Sales
3/31/2021 3/31/2020 % Change 3/31/2021 3/31/2020
Selling and administrative expenses $744 $690 8% 13.4% 14.6%
Advertising costs 566 461 23 10.2 9.7
Research and development costs 104 103 1 1.9 2.2

Selling and administrative expenses, as a percentage of net sales, decreased by 180 basis points and 120 basis points in the current three and nine month periods, respectively. The change in the current three month period was primarily due to lower incentive compensation expenses. The change in the current nine month period was primarily due to increased investments in several growth opportunities.

Advertising costs, as a percentage of net sales, increased by 90 basis points and 50 basis points in the current three and nine month periods, respectively. The increase in advertising expenses reflected the Company’s continued support behind its brands. The Company’s U.S. retail advertising spend as a percentage of net sales was approximately 12% in the current and prior three month periods.

Research and development costs, as a percentage of net sales, decreased by 40 basis points and 30 basis points in the current three and nine month periods, respectively. The decrease in research and development expenses was primarily due to lower incentive compensation expenses in the current three month period. The Company continues to invest behind product innovation and cost savings.

Goodwill, trademark and other asset impairments, Interest expense, Other (income) expense, net, and the effective tax rate on earnings

Three Months Ended 3/31/2021 3/31/2020 Nine Months Ended 3/31/2021 3/31/2020
Goodwill, trademark and other asset impairments $329 $— $329 $—
Interest expense 25 24 74 74
Other (income) expense, net 10 19 (85) 16
Effective tax rate on earnings (losses) (1.4)% 18.9% 22.5% 20.4%

Goodwill, trademark and other asset impairments of $329 in the current three and nine month periods reflect non-cash impairment charges related to goodwill, trademarks, and other assets held by the VMS business (included within the Health and Wellness segment). See Notes to Condensed Consolidated Financial Statements for further information.

Other (income) expense, net was $10 and $19 in the current and prior three month periods, respectively, and ($85) and $16 in the current and prior nine month periods, respectively. The variance between the current and prior three month periods was not significant. The variance between the current and prior nine month periods was primarily due to the one-time, non-cash remeasurement gain recognized in the current period from the Company’s previously held equity interest in the Saudi joint venture in the first quarter of fiscal year 2021 (see Notes to Condensed Consolidated Financial Statements).

The effective tax rate on earnings (losses) was (1.4)% and 22.5% for the current three and nine month periods, respectively, and 18.9% and 20.4% for the prior three and nine month periods, respectively. The substantially lower tax rate on loss before income taxes in the current three month period and higher tax rate on earnings before income taxes in the current nine month period were driven by the partial non-deductibility of impaired VMS goodwill.

Diluted net earnings (losses) per share

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Diluted net earnings (losses) per share $(0.49) $1.89 (126)% $4.78 $4.94 (3)%

Diluted net earnings (losses) per share (EPS) decreased by $2.38, or 126%, in the current three month period, primarily due to the non-cash impairment charges on assets held by the VMS business and lower gross margin, partially offset by lower selling and administrative expenses.

Diluted net earnings per share decreased by $0.16, or 3%, in the current nine month period, primarily due to the non-cash impairment charges on assets held by the VMS business, increased advertising investments and higher selling and administrative expenses, partially offset by gross margin expansion and the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture.

SEGMENT RESULTS

The following presents the results of operations from the Company’s reportable segments and certain unallocated costs reflected in Corporate (see Notes to Condensed Consolidated Financial Statements for a reconciliation of segment results to consolidated results):

Health and Wellness

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Net sales $680 $736 (8)% $2,310 $1,944 19%
Earnings (losses) before income taxes (183) 210 (187) 315 514 (39)

Volume, net sales and earnings (losses) before income taxes decreased by 11%, 8% and 187%, respectively, during the current three month period. The volume and sales decreases were primarily driven by lower shipments in Cleaning and Professional Products as well as supply constraints for some key products. The variance between volume and net sales was primarily due to lower trade promotion spending. The decrease in earnings (losses) before income taxes in the current period was primarily due to the non-cash impairment charges on assets held by the VMS business, higher manufacturing and logistics costs, and net sales decline.

Volume, and net sales increased by 15%, and 19%, respectively, and earnings before income taxes decreased by 39%, during the current nine month period. The volume and sales growth reflected higher shipments in Cleaning and Professional Products portfolios due to greater demand inside and outside of the home. The variance between volume and net sales was primarily due to lower trader promotion and favorable mix. The decrease in earnings before income taxes in the current period was primarily due to the non-cash impairment charges on assets held by the VMS business, higher manufacturing and logistics costs, and higher advertising investment, partially offset by net sales growth.

Household

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Net sales $510 $480 6% $1,421 $1,183 20%
Earnings before income taxes 97 114 (15) 266 190 40

Volume and net sales increased by 4% and 6%, respectively, and earnings before income taxes decreased by 15%, during the current three month period. The volume growth reflected higher shipments in Grilling from higher consumer demand. The variance between volume and net sales was primarily due to favorable mix and lower trade promotion spending. The decrease in earnings before income taxes was mainly due to higher manufacturing and logistics costs, unfavorable commodity costs, and higher advertising investments, partially offset by net sales growth.

Volume, net sales and earnings before income taxes increased by 14%, 20% and 40%, respectively, during the current nine month period. The volume growth reflected higher shipments across all SBUs, primarily driven by strong consumer demand. The variance between volume and net sales was primarily due to favorable mix and lower trade promotion spending. The increase in earnings before income taxes was mainly due to net sales growth, partially offset by higher manufacturing and logistics costs and higher advertising investments.

Lifestyle

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Net sales $293 $294 —% $928 $856 8%
Earnings before income taxes 68 80 (15) 259 242 7

Volume and earnings before income taxes decreased by 1% and 15%, respectively, and net sales were essentially flat during the current three month period as compared to the prior period. The volume decrease was primarily driven by lower shipments of Natural Personal Care and Brita water filtration products, partially offset by higher shipments in Food products. The decrease in earnings before income taxes was primarily due to higher manufacturing and logistics costs.

Volume, net sales and earnings before income taxes increased by 8%, 8% and 7%, respectively, during the current nine month period. Both volume growth and net sales growth were primarily driven by higher shipments of Food and Brita water filtration products mainly due to greater demand by consumers and strategic brand investments. The Natural Personal Care business declined as the brand continued to adapt to new consumer shopping and usage habits. The increase in earnings before income taxes was primarily due to net sales growth, partially offset by higher manufacturing and logistics costs.

International

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Net sales $298 $273 9% $880 $755 17%
Earnings before income taxes 30 36 (17) 184 106 74

Volume and net sales increased by 2% and 9%, respectively, and earnings before income taxes decreased by 17% during the current three month period. The volume increase was driven by higher shipments from ongoing demand for disinfecting and other household products in most geographic regions, as well as the impact of the Saudi joint venture acquisition. The variance between volume and net sales was mainly due to favorable mix and the benefit of price increases implemented to offset inflation in certain markets, partially offset by the impact of unfavorable foreign currency exchange rates. The decrease in earnings before income taxes was primarily due to higher manufacturing and logistics costs, unfavorable foreign currency exchange rates and higher commodity costs, partially offset by net sales growth.

Volume, net sales and earnings before income taxes increased by 13%, 17% and 74%, respectively, during the current nine month period. The volume increase was primarily driven by higher shipments from ongoing demand for disinfecting and other household products in every geographic region, as well as the impact of the Saudi joint venture acquisition. The variance between volume and net sales was mainly due to favorable mix and the benefit of price increases implemented to offset inflation, partially offset by the impact of unfavorable foreign currency exchange rates. The increase in earnings before income taxes was primarily due to the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture.

Argentina

Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, and as a result the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina are recognized in Other (income) expense, net in the consolidated statement of earnings. The business environment in Argentina continues to be challenging due to significant volatility in Argentina’s currency, high inflation, an economic recession and impacts of COVID-19 that include temporary strict price controls. As of March 31, 2021 and June 30, 2020, the net asset position, excluding goodwill, of Clorox Argentina was $45 and $44, respectively. Of these net assets, cash balances were approximately $9 and $19 as of March 31, 2021 and June 30, 2020, respectively. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for the nine months ended March 31, 2021 and the fiscal year ended June 30, 2020.

For additional information on the impacts of, and our response to, the business environment in Argentina, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

Corporate

Corporate includes certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses.

Three Months Ended 3/31/2021 3/31/2020 % Change Nine Months Ended 3/31/2021 3/31/2020 % Change
Losses before income taxes $(71) $(143) (50)% $(225) $(262) (14)%

Losses before income taxes decreased by $72 in the current three month period primarily due to lower employee and incentive compensation and COVID-19 related expenses. Losses before income taxes decreased by $37 in the current nine month period primarily due to lower COVID-19 related expenses.

FINANCIAL POSITION AND LIQUIDITY

The Company’s financial condition and liquidity remained strong as of March 31, 2021. The following table summarizes cash activities:

Nine Months Ended 3/31/2021 3/31/2020
Net cash provided by operations $893 $806
Net cash used for investing activities (341) (145)
Net cash used for financing activities (944) (261)

Operating Activities

Net cash provided by operations was $893 in the current nine month period, compared with $806 in the prior nine month period. The increase was primarily driven by the Company’s profitable sales growth, partially offset by higher tax payments and higher employee incentive compensation payments made in the current nine month period versus the prior period. Working capital changes were essentially flat in the comparative period (increased inventories in the current year primarily to meet customer demand, offset by cash inflows from collections from increased quarter-end sales in the prior fiscal year, and higher payables in the current period due to the extension of payment terms with suppliers and increased production levels primarily to improve inventory availability).

Investing Activities

Net cash used for investing activities was $341 in the current nine month period, compared with $145 in the prior nine month period. The year-over-year increase was mainly due to the acquisition of additional interest in the Company's Saudi joint venture and higher capital spending to increase manufacturing capacity in the current nine month period.

Financing Activities

Net cash used for financing activities was $944 in the current nine month period, compared with $261 in the prior nine month period. The year-over-year increase was mainly due to higher treasury stock repurchases in the current nine month period and net cash sourced from short-term borrowings in the prior period.

Capital Resources and Liquidity

Global financial markets have experienced a significant increase in volatility due to heightened uncertainty over the adverse economic impact caused by the COVID-19 outbreak. Notwithstanding these potential adverse market conditions, the Company believes it will have the funds necessary to support our short-term liquidity and operating needs based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings, and current borrowing availability under the credit agreement.

Credit Arrangements

As of March 31, 2021, the Company maintained a $1,200 revolving credit agreement that matures in November 2024 (the Credit Agreement). There were no borrowings under the Credit Agreement as of March 31, 2021 and June 30, 2020, and the Company believes that borrowings under the Credit Agreement are and will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0, calculated as total earnings before interest, taxes, depreciation and amortization and other similar non-cash charges (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement. Refer to the section entitled “Non-GAAP Financial Measures” below for further discussion of these measures.

The following table sets forth the calculation of the Interest Coverage ratio as of March 31, 2021, using Consolidated EBITDA for the trailing four quarters, as contractually defined in the Credit Agreement:

Twelve Months Ended 3/31/2021
Net earnings $929
Add back:
Interest expense 99
Income tax expense 265
Depreciation and amortization 204
Non-cash asset impairment charges(1) 330
Deduct:
Interest income (4)
Non-recurring, non-cash gain(2) (85)
Consolidated EBITDA $1,738
Interest expense $99
Interest Coverage ratio 17.6

(1) Includes goodwill, trademark and other asset impairments recorded impacting the VMS SBU (see Notes to Condensed Consolidated Financial Statements)

(2) Non-recurring, non-cash gain from the remeasurement of the Company’s previously held investment in its Saudi joint venture (see Notes to Condensed Consolidated Financial Statements).

The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of March 31, 2021, and anticipates being in compliance with all restrictive covenants for the foreseeable future. The Company continues to monitor the financial markets and assess its ability to continue to draw on the Credit Agreement, and currently expects it will continue to have access to borrowings under the Credit Agreement.

As of March 31, 2021, the Company maintained $35 of foreign and other credit lines, of which $8 was outstanding.

Stock Repurchases and Dividend Payments

As of March 31, 2021, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.

Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:

Three Months Ended 3/31/2021 Amount Shares (in thousands) 3/31/2020 Amount Shares (in thousands) Nine Months Ended 3/31/2021 Amount Shares (in thousands) 3/31/2020 Amount Shares (in thousands)
Open-market purchase program $200 1,088 $— — $200 1,088 $85 577
Evergreen Program 105 560 30 184 405 1,984 134 847
Total stock repurchases $305 1,648 $30 184 $605 3,072 $219 1,424

Dividends per share declared and total dividends paid to Clorox stockholders were as follows for the periods indicated:

Three Months Ended 3/31/2021 3/31/2020 Nine Months Ended 3/31/2021 3/31/2020
Dividends per share declared $1.11 $1.06 $3.33 $3.18
Total dividends paid 140 133 420 399

28

CONTINGENCIES

See Notes to Condensed Consolidated Financial Statements for information on the Company’s contingencies.

RECENTLY ISSUED ACCOUNTING STANDARDS

See Notes to Condensed Consolidated Financial Statements for a summary of recently issued accounting standards relevant to the Company.

NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures that are included in this MD&A and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.

The Company uses the term Consolidated EBITDA because it is a term used in the Credit Agreement. As defined in the Credit Agreement, Consolidated EBITDA represents earnings before interest, taxes, depreciation and amortization, and other similar non-cash charges (such as non-cash asset impairment charges and other non-cash, non-recurring gains or losses). Interest Coverage ratio is the ratio of Consolidated EBITDA to interest expense. The Company’s management believes disclosure of Consolidated EBITDA provides useful information to investors because it is used in determining compliance with the primary restrictive covenant in the Credit Agreement. For additional discussion of the Interest Coverage ratio and a reconciliation of Consolidated EBITDA to net earnings, see “Financial Position and Liquidity - Financing Activities - Credit Arrangements” above.

Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions and divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the Company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the Company and management.

The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:

Three Months Ended March 31, 2021 Percentage change versus the year-ago period Health and Wellness Household Lifestyle International Total
Net sales growth / (decrease) (GAAP) (8)% 6% —% 9% —%
Add: Foreign Exchange — — — 2 —
Add/(Subtract): Divestitures/Acquisitions — — — (7) (1)
Organic sales growth / (decrease) (non-GAAP) (8)% 6% —% 4% (1)%
Nine Months Ended March 31, 2021
Percentage change versus the year-ago period
Health and Wellness Household Lifestyle International Total
Net sales growth / (decrease) (GAAP) 19% 20% 8% 17% 17%
Add: Foreign Exchange — — — 4 —
Add/(Subtract): Divestitures/Acquisitions — — — (8) (1)
Organic sales growth / (decrease) (non-GAAP) 19% 20% 8% 13% 16%

29

Cautionary Statement

This Report, including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the COVID-19 pandemic, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings attributable to the Company, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the Company’s ability to achieve its strategic goals, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 and in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to, the uncertainties relating to the continued impact of COVID-19 on the Company’s business, operations, employees, financial condition and results of operations, as well as:

  • intense competition in the Company’s markets;
  • the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;
  • the impact of COVID-19 on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any significant disruption to such systems;
  • long-term changes in consumer preference or demand for the Company’s products as a result of any shortages or lack of availability of any products in the near-term;
  • risks related to supply chain issues and product shortages as a result of reliance on a limited base of suppliers and the significant increase in demand for disinfecting and other products due to the COVID-19 pandemic;
  • dependence on key customers and risks related to customer consolidation and ordering patterns;
  • risks related to the Company’s use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions, especially at a time when a large number of the Company’s employees are working remotely and accessing its technology infrastructure remotely;
  • risks relating to acquisitions, including the recent acquisition of the majority interest in the company’s Saudi joint venture, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks, and goodwill, in particular the impairment charges relating to the carrying value of the company’s Vitamins, Minerals and Supplements business;
  • unfavorable worldwide, regional and local economic and financial market conditions, including as a result of fear of exposure to or actual impacts of a widespread disease outbreak, such as COVID-19;
  • the Company’s ability to maintain its business reputation and the reputation of its brands and products;
  • lower revenue, increased costs or reputational harm resulting from government actions and regulations;
  • the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;
  • the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;
  • volatility and increases in commodity costs such as resin, sodium hypochlorite and agricultural commodities, and increases in energy, transportation or other costs;
  • risks related to international operations and international trade, including foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls, including periodic changes in such controls; changes in U.S. immigration or trade policies, including the imposition of new or additional tariffs; labor claims and labor unrest; inflationary pressures, particularly in Argentina; impact of the United Kingdom’s exit from, and the related on-going negotiations with, the European Union; government-imposed price controls or other regulations; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;
  • the facilities of the Company and its suppliers being subject to disruption by events beyond the Company’s control, including work stoppages, cyber-attacks, natural disasters, disease outbreaks or pandemics, such as COVID-19, and terrorism;
  • the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;
  • the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls;
  • the ability of the Company to implement and generate cost savings and efficiencies;
  • the success of the Company’s business strategies;
  • risks related to additional increases in the estimated fair value of The Procter & Gamble Company’s interest in the Glad business;
  • the accuracy of the Company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based;
  • the Company’s ability to attract and retain key personnel;
  • environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;
  • increased focus by governmental and non-governmental organizations, customers, consumers and investors on sustainability issues, including those related to climate change;
  • the Company’s ability to effectively utilize, assert and defend its intellectual property rights;
  • any infringement or claimed infringement by the Company of third-party intellectual property rights;
  • the effect of the Company’s indebtedness and credit rating on its business operations and financial results;
  • the Company’s ability to access capital markets and other funding sources, as well as continued or increased market volatility;
  • the Company’s ability to pay and declare dividends or repurchase its stock in the future;
  • uncertainties relating to tax positions, tax disputes and any changes in tax rates and regulations on the Company;
  • the Company’s ability to maintain an effective system of internal controls;
  • the impacts of potential stockholder activism; and
  • risks related to the Company’s discontinuation of operations in Venezuela.

The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.

Market risk

As filed, 325 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have not been any material changes to the Company’s market risk since June 30, 2020. For additional information, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

Controls and procedures

As filed, 1,162 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

No change in the Company’s internal control over financial reporting occurred during the third fiscal quarter of the fiscal year ending June 30, 2021, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-01-01 to 2021-03-31$1.78bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-07-01 to 2021-03-31$5.54bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-01-01 to 2021-03-31$1.01bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2020-07-01 to 2021-03-31$3.01bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-01-01 to 2021-03-31$774.0mus-gaap:GrossProfit
Gross profit9 months2020-07-01 to 2021-03-31$2.53bnus-gaap:GrossProfit
Research and development3 months2021-01-01 to 2021-03-31$32.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-07-01 to 2021-03-31$104.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-01-01 to 2021-03-31$237.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-07-01 to 2021-03-31$744.0mus-gaap:SellingGeneralAndAdministrativeExpense
Interest expense3 months2021-01-01 to 2021-03-31$25.0mus-gaap:InterestExpense
Interest expense9 months2020-07-01 to 2021-03-31$74.0mus-gaap:InterestExpense
Income tax3 months2021-01-01 to 2021-03-31$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-07-01 to 2021-03-31$180.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-01-01 to 2021-03-31−$61.0mus-gaap:NetIncomeLoss
Net income9 months2020-07-01 to 2021-03-31$613.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-01-01 to 2021-03-31−$0.49us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-07-01 to 2021-03-31$4.78us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-01-01 to 2021-03-31−$0.49us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-07-01 to 2021-03-31$4.86us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-01-01 to 2021-03-31125,610,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-07-01 to 2021-03-31128,030,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-07-01 to 2021-03-31$893.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-07-01 to 2021-03-31$232.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2020-07-01 to 2021-03-31$420.0mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2020-07-01 to 2021-03-31$605.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-03-31$492.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-03-31$1.96bnus-gaap:AssetsCurrent
Total assetsAt period end2021-03-31$6.44bnus-gaap:Assets
Current liabilitiesAt period end2021-03-31$1.82bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-03-31$5.50bnus-gaap:Liabilities
Long-term debtAt period end2021-03-31$2.48bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2021-03-31$300.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2021-03-31$743.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000021076-21-000009. Last ingested by Listed: Nov 10, 2026, 22:57 ET. Listed shows no prices and gives no investment advice.